Omacetaxine Mepesuccinate

高三尖杉酯碱

Report date: 2022/01/14 13:23:58
NMEFirst In Class

Base Information

Drug NameOmacetaxine Mepesuccinate
Drug Alias NameHomoharringtonine美琥他辛美培琥奥玛他星mepesuccinato de omacetaxinaomacetaxini mepesuccinas +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein biosynthesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesProstatic Neoplasms +[9] 
Global Approved IndicationsMyelodysplastic SyndromesPolycythemia VeraLeukemia, Myelogenous, Chronic
Approved Indications in ChinaMyelodysplastic SyndromesPolycythemia VeraLeukemia, Myelogenous, Chronic
Original Approved Country/TerritoryMainland China
Original Approved Date1991/01/01
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTeva
China Registration ClassN/A

Develop Information

Active CompaniesThe Affiliated Tumor Hospital Of Nantong University, Nantong, Jiangsu Province, ChinaNantong First People'S HospitalSubei People's Hospital of Jiangsu Province +[4] 
Inactive CompaniesTeva Pharmaceuticals International GmbhChemgenex Pharmaceuticals IncNational Cancer Institute +[8] 
Active IndicationsMyelodysplastic SyndromesProstatic NeoplasmsPolycythemia Vera +[4] 
Inactive IndicationsSolid tumoursHematologic NeoplasmsLeukemia, Myeloid, Acute +[5] 

Other Information

ATC CodeL01XX40
Related LinksWikipediaDrugBankKEGG